

UC Berkeley

Research and Occasional Papers Series

Title

University Roles in Technological Innovation in California

Permalink

<https://escholarship.org/uc/item/3f0384w8>

Author

King, C. Judson

Publication Date

2007-05-31

Research & Occasional Paper Series: CSHE.6.07

CSHE | Center for Studies in Higher Education

University of California, Berkeley
<http://cshe.berkeley.edu>

UNIVERSITY ROLES IN TECHNOLOGICAL INNOVATION IN CALIFORNIA¹

May 2007

C. Judson King²

University of California, Berkeley

Copyright 2007 C. Judson King, all rights reserved.

ABSTRACT

California has achieved considerable economic success through technological innovation and the formation of businesses based upon those technologies. This paper addresses some of the roles of universities in that success story. It starts with some measures of the contributions of innovation and a robust university structure to the California economy, drawn from the biotechnology and wine industries. This is followed by an exploration of some recent partnership structures involving universities with industry and/or the state government. Emphasis is on the University of California, since that is where the experience of the author lies. This is followed by considerations of how such partnerships can be most successful and at the same time meet concerns about potential undesirable consequences stemming from them.

Introduction

The public universities in the United States were established with the goals of providing widespread, affordable access to higher education. Starting with agriculture and the mechanical arts well over a century ago, it has been increasingly recognized that another important role of research universities, public and private, is in building the economy and improving societal conditions through innovation. This role has been well appreciated in California for the electronics, software, biotechnology and communications industries, and in other areas such as health care and agriculture.

The purposes of this paper are to indicate some of the ways in which universities, and the University of California in particular, have contributed to the development of California industries, to explore several recent organized structural and project efforts

¹ Prepared for Salzburg Seminar No. 441, "From Lab to Market: Accelerating Innovation through University, Business, and Government Partnership", April 28 – May 3, 2007, Salzburg, Austria. Copyright reserved to the author.

² The author is Provost and Senior Vice President – Academic Affairs, Emeritus of the University of California. He is also Professor of Chemical Engineering, Emeritus, and Director, Center for Studies in Higher Education on the Berkeley campus. He has been associated with the California Council on Science and Technology since 1994 and chaired that Council, 2002-04.

that are various forms of university, industry and/or government partnerships, and to assess some of the most important factors for success and for meeting concerns about any detrimental effects of such partnerships.

Some Measures of Impact

The broadest contributions of California universities, or indeed universities anywhere, to the state are the educational development of the populace and the flow of graduates at all degree levels to positions in business, government, universities, and self-employment. Influences that are more specific to technological innovation are the education of holders of graduate and professional degrees, the flow to industry of inventions and relevant background information stemming from university research, and transitions of faculty and senior researchers to roles as entrepreneurs themselves.

A sampling of facts and figures pertaining to the biotechnology and wine industries provides more specific examples.

Biotechnology

Yarkin and Murray¹ have studied the flow of people from the University of California to the California biotechnology industry and the contributions that they have made to the development of that industry. In 2001, stemming from the original 1980 Cohen (Stanford University) and Boyer (University of California) patent on recombinant DNA technology² and subsequent research,

- More than one-third of U.S. biotechnology companies were situated in California.
- These companies accounted for more than 47% of research expenditures of the U.S. biotechnology industry and accounted for 53% of revenues.
- The California biotechnology industry provided 60,000 jobs at an average salary of \$71,000, i. e., \$4.3 billion of personal income.
- At least 35% of California biotechnology firms were founded by University of California faculty.
- At least 302 persons with University of California Ph.Ds were working in California biotechnology companies
- Licenses to technology from the University of California were held by 82 biotechnology companies.
- Large clusters of biotechnology companies existed in the San Francisco Bay Area and San Diego, and 96% of California biotechnology companies were located within 35 miles of a University of California campus.

A less detailed companion study deals with the R&D-intensive communications industry³.

Wine and Viticulture

Historically, another very tangible contribution of University of California research has been to the development of the California wine industry⁴. Interestingly, the University of California programs in viticulture and enology originated through an act of the state legislature in 1880. Policy makers apparently sensed the economic potential of the industry and mandated that the state university take on the task of improving it. This research has largely been carried out at the University Farm at Davis, which became the

Davis campus. During the period of Prohibition in the United States (1919-1933), research was carried out on viticulture, leading to the development of plant strains used now for more than 95% of wine made in the United States and much of that made in other countries. Research in the 1930s focused upon the influence of climate on growth of different varietals, leading to knowledge that underlies site locations for vineyards around the world. The Davis campus also developed malo-lactic fermentation, which allows the wine-making process to be chemically controlled to produce distinctive flavors and to exercise quality control. Maynard Amerine and associates at UC Davis developed a methodology of sensory evaluation that is in widespread use today. Nearly all wineries in the United States now have a UC Davis alumnus as wine maker or manager. As well, students are sent to the UC Davis enology and viticulture programs from wine-making countries around the world. It is this long-term, sustained line of research that has made California wines excellent and highly competitive.

As of 2005⁵, the California wine industry:

- Contributed \$51.8 billion to the California state economy and \$125.3 billion to the U.S. economy.
- Created 309,000 full-time-equivalent jobs in California, with \$10.1 billion gross wages.
- Sold 74% of its output in the other 49 states, creating 875,000 jobs in the United States as a whole.
- Paid \$3.2 billion in taxes and license fees to the state of California, and \$1.8 billion in federal taxes to the U.S. government.
- Contributed more than 95% of U.S. wine exports, which totaled \$658 million⁶.

The developments of the biotechnology industry and the wine industry are but two examples of the contribution of university research and industry-university-government research projects to the economy of California. The role of university research in the development of California agriculture in general is another prime example. A recent consultant report explores the economic, health and cultural contributions of the University of California more widely⁷.

Structural Organization and Support Initiatives

It is important to recognize that California achieved its status and reputation as a center for technological and entrepreneurship without a grand design or substantial stimulation by the state government or other organized entities. The necessary ingredients were there, and the flower blossomed on its own. As one prominent example, the origins and reasons for the success of Silicon Valley are well analyzed in a classic work by Saxenian⁸. Silicon Valley worked so well because of cultural factors and modes of interaction that were peculiar to California. That Stanford University and the Berkeley campus of the University of California were close at hand was also important, as was the fact that the early, post-World War II development of what became Silicon Valley was favored and fostered by the Stanford Provost, Frederick Terman⁹.

Structured organizational and supporting initiatives came later. This paper explores six of these, in rough chronological order.

MICRO and Industry-University Cooperative Research Programs

Launched in 1981, the MICRO Program is designed “to support innovative research in microelectronics technology, its applications in computer and information sciences, and its necessary antecedents in other physical science disciplines.”¹⁰ The program involves industrial grants for research at the University of California, supplemented with matching state funds expressly designated for the program. The state and the university waive the usual university overhead charges for these projects. The program is overseen by a Policy Board with representatives from the state, industry, and the university. Peer review plays a strong role.

While the design of the program is not all that unusual, the size and success are. More than 500 companies have participated in the program over the years. In the year 2005-2006, 97 companies supplied \$6.5 million for 104 projects, with another \$3.8 million coming through the program from state funds, and yet another \$3+ million corresponding to waived overhead.

In 1996, MICRO was augmented by the creation of the Industry-University Cooperative Research Program (I/UCRP)¹¹. This program gives what are now known as Discovery Grants in a manner similar to MICRO, except that indirect costs are not waived. Five fields are covered: biotechnology, communications and networking, digital media, electronics manufacturing and new materials, and information technology for life sciences. Since the 1996 inception of the program, 777 projects have been funded. Currently, on an annual basis, about \$22 million of state and UC funds bring in about \$36 million from industry. By any measure, these programs are a large success, serving to bring university researchers together with industrial scientists and engineers and contributing substantially through their outputs to the state economy. The programs fit the needs of both state industry and university research well.

UC CONNECT

In 1985, working with the San Diego business community, the San Diego campus of the University of California formed UC CONNECT¹², an organization designed to facilitate the development of entrepreneurial businesses in the region. The organization is free-standing and connects entrepreneurs with technology, money, markets, management, partners, and support services. Approaches used include consultation regarding support resources for start-up ventures, networking events, educational opportunities, and recognition of outstanding accomplishments. In many respects, CONNECT is an organized effort aimed at replicating what occurred naturally in Silicon Valley. It recognized the need for these diverse services and networking in order for technological innovation to occur in as unimpeded fashion as possible. CONNECT has been an important player in the establishment of the biotech and wireless communications industries in San Diego. It has since been replicated at the Davis campus of the University of California¹³, as well as in Scotland, Denmark, Norway, Sweden, and Taiwan¹⁴

California Council for Science and Technology

Founded in 1988 as a not-for-profit corporation through enabling legislation from the state, the California Council on Science and Technology¹⁵ (CCST) emulates the roles that the National Research Council and the National Academies have at the federal level. The Council consists of 30 members, supplemented by a much larger number of Fellows, who are scientists, engineers and technology leaders drawn from California’s

universities, corporations, and national laboratories. Council members are appointed for once-renewable three-year terms. Studies are undertaken at the request of branches of state government, with the nature of the request often being developed jointly with CCST, at the initiative of either body. Project funding comes from state agencies and private foundations. A series of recent studies have dealt with the environment for science and technology in California, a critical-path analysis of the science and technology system within the state, and a critical-path analysis of the production of math and science teachers within California. Other projects include a series of reviews of the state's \$60 million Public Interest Energy Research Program and development of a recommended policy framework for intellectual property developed through state-funded research.

CCST studies generally get attention and action because the request originates from within state government. Because of the lack of a state Science Advisor or Office of Science and Technology, CCST carries some of the roles that fall to the science advisor on the federal level. Examples include advising on recent landmark legislation for greenhouse-gas reduction and low-carbon fuel standards, analysis of the issues surrounding use of hydrogen as a fuel, and suggestions for components of a state science initiative.

California Technology, Trade and Commerce Agency

The California Technology, Trade and Commerce Agency (TTCA) was established in 1992 as an agency in state government. The missions of the agency were to promote business, employment, and trade, as well as economic competitiveness in general. The agency was also the primary state vehicle for projects associated with conversions of military bases to civilian uses. In addition, it had a \$6 million program that gave matching grants of up to \$200,000 for proposals to federal government agencies made by entities within the state for projects that held the potential of developing technology-based business in California. Reflecting political contention over the appropriateness of this role and a seeming consensus that the value added by the agency was not large, TTCA was discontinued in 2003.

California Institutes for Science and Innovation

Four major research institutes were launched in the year 2000, as a gubernatorial initiative to support the role of innovation in spurring the California economy. As originally defined, the initiative provided \$100 million for each of three institutes, spread over four years, with a requirement that the institutes raise even greater funds as a 2:1 match. The institutes were to be on University of California campuses and would carry out research in fields believed to be promising for the economic growth of the state. They were envisioned as catalytic partnerships between university research and private industry that could expand the state economy into new industries and "speed the movement of innovation from the laboratory into people's daily lives" (Governor Gray Davis's Budget Summary, 2001-02).¹⁶

The university held an internal competition, encouraging multi-disciplinary approaches and involvement of multiple campuses. Topics for the institutes were not specified; instead, identifying the topics was a part of the competition. Final proposals were subjected to extensive peer review and were judged by a multi-dimensional, highly distinguished panel, external to the university. The use of a competition was essential to the quality of the proposals, as well as effective multi-disciplinary and multi-campus

design. Because of the strength of the ultimate proposals, a fourth institute was funded by the state as well.

The four institutes are:

- California Institute for Telecommunications and Information Technology [Cal-(IT)²] – San Diego and Irvine campuses
- California Institute for Quantitative Biomedical Research [QB3] – San Francisco, Berkeley and Santa Cruz campuses
- California Nanosystems Institute [CNSI] – Los Angeles and Santa Barbara campuses
- Center for Information Technology Research in the Interest of Society [CITRIS] – Berkeley, Davis, Merced and Santa Cruz campuses

The needed match (\$800 million) was a very large sum, yet it was raised and then some, with the total match being more than \$1 billion. The acquisition of these matching funds was facilitated by having the competition, since it was clear for donors that the match would be required to bring the particular institute into existence. The fact that the subject matters of the institutes were not specified before the competition provided yet another incentive for corporations to provide funding, since the institute in question would have to be selected in order for there to be an institute matching the particular interests of a corporation. The matching funds were raised primarily from industry for three of the institutes and primarily as federal government funds for the fourth (CNSI).

Because of the nature of the state budgetary situation, the state funding was almost totally for capital expenditures. Thus the state funding has gone primarily into building the campus facilities that bring the researchers of an institute together. Core operating funds have been more of a problem, but \$20 million of operating funds annually are now part of the new \$95 million Research and Innovation Initiative in the 2007-08 California governor's budget.¹⁷

California Institute for Regenerative Medicine

The California Institute for Regenerative Medicine (CIRM) is an organization that came into being in a very different way. California has a system of direct initiative ballot referenda that can be, and often are, used to enact laws directly by popular vote. For the first time, this approach was used in 2004 to establish a program of scientific research, through an initiative entitled the California Stem Cell Research and Cures Act. It created the California Institute for Regenerative Medicine¹⁸ to administer an "average of \$295 million per year in bonds over a ten-year period to fund stem cell research and dedicated facilities for scientists at California's universities and other advanced medical research facilities throughout the state".¹⁹ CIRM is overseen by an Independent Citizen's Oversight Committee (ICOC) with a specified composition appointed by designated officials and consisting of persons from specific, designated backgrounds. The initiative language is added to the state constitution, cannot be amended for three years, and requires 70% of the votes from both houses of the legislature, along with approval by the Governor, in order to be revised or eliminated thereafter. Thus, it is popularly described as "iron clad."

This initiative did not arise institutionally from universities themselves. The prime mover was a group of advocates for medical cures and stem-cell research. The ballot proposition was promoted heavily, and indeed named, from the standpoint that stem-cell

research would lead to therapy for incurable diseases such as diabetes, spinal-cord injury and Alzheimer's disease.²⁰ The initiative was a very visible and tangible step placing California as a state in a forefront position within the United States in stem-cell research, as contrasted with federal policy which is currently quite restrictive.

The ability of the state to sell the bonds has been held up in a legal process initiated by those who oppose the use of embryonic stem cells for research. Meanwhile, support of research has commenced, drawing from a \$150 million loan from state general funds, authorized by the governor, supplemented by loans and gifts from private California foundations and individuals.

The initiative states that "the ICOC shall establish standards that require that all grants and loan awards be subject to intellectual property agreements that balance the opportunity of the State of California to benefit from the patents, royalties and licenses that result from basic research, therapy development and clinical trials with the need to assure that essential medical research is not unreasonably hindered by the intellectual property agreements." This language has muddied already unclear waters on ownership of intellectual property from state-funded research. This language and expectations of close-at-hand profitability stemming from the marketing of the initiative have led to considerable controversy surrounding ways in which the State of California can "recover" some of its investment in this and other research.

This venture, still ongoing, exhibits what can happen when the funding of research is tied so closely to the political process. Although, when all is said and done, much good may come of research sponsored through CIRM, the research itself and the research world in general may well suffer from science becoming such an activist force in the political process and from the unrealistic expectations and constant public scrutiny thereby generated. It may also lead to other efforts to use the same process for restrictive new funding of research. Indeed, there has already been another such initiative in 2006²¹, modeled on the earlier stem-cell initiative, which would have taxed producers of oil extracted in California to generate a fund of \$4 billion over time, 27% of which would have been used for research on reduction of petroleum usage, renewable energy, energy efficiency and alternative fuel technologies and products. It did not pass, reflecting in part after-the-fact voter dissatisfaction with the stem-cell initiative.

Project-Oriented Initiatives

In addition to the structures and mechanisms described above, there are four recent, major, California-based, industry-university project initiatives that deserve consideration in connection with the theme of this paper.³

Novartis Agreement with UC Berkeley

In 1998, a controversial research agreement was made between the Berkeley campus of the University of California and Novartis, a large Swiss pharmaceutical and biotechnology company. This arrangement is one of many made between large biotechnology/pharmaceutical companies and major universities over the years,

³ I should point out that I was not involved in the creation or review of any of these project partnerships in my administrative capacities at the University of California. The opinions expressed concerning them are solely my own as a hopefully objective observer.

reflecting the very close relationship between academic research and commercial innovation within that field. However, it was unique in its design and in that it made such a sizeable arrangement between a commercial firm and a public university. A useful and insightful analysis of the drivers for the arrangement and the benefits and concerns has been made by LaPorte.²²

The agreement²³ followed a formal, two-year process in which the College of Natural Resources of the Berkeley campus solicited proposals from six major corporations, with four responding. By the terms of the agreement, Novartis contributed \$5 million per year for five years, or \$25 million total, for support of research in the Department of Plant and Microbial Biology. This was about 30% of the total extramurally funded research budget of the department. The portion of the funds devoted to overhead was 33%, covering renovations, support of the general graduate program, and general campus overhead.

Another very important component was access by Berkeley researchers on a confidential basis to the Novartis agricultural genomic database, coupled with \$3 million for a Novartis facility near the campus with workstations through which that database could be accessed and advisory Novartis employees to help with access. The value of this aspect of the arrangement lay in the fact that a substantial amount of genomic data are confidential to large companies, thereby placing the academic sector in a situation where they carry out research without full access to the available knowledge base.

In return, Novartis received first rights to license a percentage of inventions from research in the department, whether or not supported with actual Novartis funds. That percentage was the ratio of the Novartis funding to the total departmental extramural research support, cited as a method of calculation recommended by National Institutes of Health guidelines for arrangements involving both NIH and private support. Novartis also received the conventional thirty-day opportunity to review potential publications for patentable items, and an additional sixty days if the decision was made to patent. Such a component of industry-university agreements is not unusual.

The project was overseen by a six-member Advisory Committee with three members from the campus (Vice Chancellor for Research, Dean and a non-involved faculty member), and three members from Novartis. There was also a five-member Research Committee, three of whom were from the campus, to award actual grants.

There were a number of concerns expressed at the time and throughout the term of the agreement. These are summarized by LaPorte (*loc. cit.*). Many of the concerns dealt with academic freedom – the right of faculty to choose and pursue research as they see fit. Those concerns eventually formed the lead item for a story in the *Atlantic Monthly*.²⁴ As the controversy continued, there was an internal review commissioned, followed by an external review undertaken at the behest of the Academic Senate with the concurrence of the administration. That review²⁵, since published as a book²⁶, concluded that academic freedom and the academic conduct of the department had not been seriously compromised. The reviewers also made a number of recommendations, one of which was that the university should consider avoiding industry agreements that involve complete academic units or comparable large groups of researchers.

During the five-year period of the agreement, there was a major restructuring of Novartis that eliminated the unit that had made the agreement. Hence renewal of the agreement became moot.

In addition to the academic-freedom issue, which was probably well enough addressed with regard to the specifics of research, the essential issue surrounding this venture was the extent to which a public institution, and an entire department within that institution, can pair themselves with a private corporation. Can academic objectivity be maintained amid such a presence? And is it appropriate for a public institution that derives substantial taxpayer support, including corporation taxes, to match itself so visibly with one corporation? Conversely, it can be argued that a large amount of the total revenue of public universities (on order of 77% for the University of California) comes from sources other than the state budget, and that corporations within the state do receive the benefit of their taxes, even when such arrangements are made with single corporations.

A final substantive issue is how confidential data can be used in publishable research while fulfilling simultaneously the requirements of the openness of science and the ability for others to seek to reproduce results.

The Artemisinin Project: Development of a Low-Cost Malaria Drug

A large and highly innovative partnership was put together in late 2004 to work towards making artemisinin, the precursor to a potent anti-malaria drug, available to the undeveloped world at a cost that will enable widespread use. Malaria strikes up to 500 million people annually, killing about 1.5 million who are mostly from very poor areas of Africa and Asia. Derivatives of artemisinin, when mixed with other substances to form artemisinin combination therapies (ACTs) and used for only three days, are nearly 100% effective in preventing deaths from malaria. Artemisinin is currently derived from the wormwood tree. Even at the current price of \$2.40 per treatment, it is too expensive for widespread use in the poor countries that are most affected.

There are four participants in the five-year project²⁷ -- the Bill and Melinda Gates Foundation, the Institute for OneWorld Health (IOWH), Amyris Biotechnologies, Inc., and the University of California, Berkeley. The aim is to use synthetic molecular biology to create artemisinic acid, a direct precursor of artemisinin, with the goal of reducing the cost of artemisinin by an order of magnitude. The Gates Foundation, with strong interests in health in underdeveloped countries, provides \$42.6 million. Of that amount, \$8 million goes to Professor Jay Keasling and his group at the Berkeley campus for pertinent research on the synthetic biology route to artemisinic acid, including engineering the microbe. Another \$12 million goes to Amyris Biotechnologies, a for-profit company, for applied research on the pertinent processing techniques. The final \$22.6 million goes to IOWH, a non-profit pharmaceutical company, which will lead development of commercialization, marketing and distribution, including meeting regulatory requirements for different countries, and analysis and improvement of ACT manufacturing, supply chain and distribution.

In contrast to most other pharmaceutical development, this partnership is designed to address the need for extremely low product cost. The Gates Foundation funds provide seed and start-up funding of a sort that would not be available from the venture-capital community. Similarly, the not-for-profit IOWH, with the Gates Foundation funding, can address the regulatory and distribution needs in ways that would not be viable in the for-profit sector. Finally, the intellectual property arrangements²⁸ are also unusual and are designed to promote low cost. The University of California has given royalty-free licenses to IOWH and to Amyris for the developing-world market, i. e., the market being

addressed by IOWH. The license to Amyris is royalty-bearing for the developed world and for uses of artemisinin other than for malaria.

A key aspect of this project lies in the incentives that attract the various partners. The university benefits from having a very visible example of the utilization of university research for a great worldwide need, as well as deriving royalties from uses for malaria in the developed world and for other purposes. The non-profit pharmaceutical company, IOWH, directly works towards its mission of making an effective malaria treatment available at a low cost in the underdeveloped world. The for-profit company, Amyris, can apply the processing technology that is developed in this project to other projects that rely upon the same platform technology; it develops a base of expertise and processing capability. The Gates Foundation has put together an effective team that can make a major contribution to world health, in underdeveloped countries in particular, thereby addressing a primary mission of the foundation.

Climate and Energy Projects

The major world needs associated with greenhouse gases and sources and utilization of energy have led to two unusually large university-industry projects located in California. One is coordinated by Stanford University and the other by the University of California, Berkeley.

Stanford Global Climate and Energy Project. In 2002, Stanford University concluded an agreement with four corporations -- Exxon Mobil, General Electric, Toyota, and Schlumberger -- for a Global Climate and Energy Project (G-CEP)²⁹. The sponsors pledged \$225 million over ten or more years to support a diverse program of pre-commercial research designed to lead to technological options for energy production, and use with reduced greenhouse gas emissions. The project supports research teams at Stanford and elsewhere, and is not restricted to university research. Stanford administers the project. In an unusual step for such a consortium and a private university, the full wording of the founding agreement is available on the Internet³⁰.

The project is governed by a Management Committee composed of single voting representatives of the four corporations, who rotate as chair, and the Project Director as a non-voting member. Subject to general approval of topical areas by the Management Committee, the Project Director and his staff oversee a peer review process whereby proposals are solicited, judged and selected for funding. Thus, in essence, the four sponsoring corporations, acting in a consortium as a funding agency, have engaged Stanford to administer a grant process to select projects, distribute funds and monitor results.

Stanford holds legal title to inventions; however, the sponsoring corporations exercise guidance as to which inventions should be pursued for patent coverage. Sponsors also have exclusive rights to commercialize inventions for the first five years, royalty-free.

It is interesting to speculate regarding the motives for the industrial partners. First, it is important that the four corporations for the most part do not compete with one another; they are in complementary lines of business. Second, the sponsors engender a broad portfolio of underlying research, from which they may draw technologies that they may wish to develop, in most cases without competition from a direct competitor.

Funding agencies run by a university are relatively rare, but do exist in other forms. For example, the University of California administers three programs of state-funded research – Breast Cancer, AIDS, and Tobacco-related Disease – that are not restricted to University of California grantees.

BP Energy Biosciences Institute. In 2006, the multi-national oil firm BP announced an intention to create an Energy Biosciences Institute, in conjunction with a major university. After preliminary explorations, BP invited five universities to form teams to submit proposals to join with BP in an Energy Biosciences Institute, which would be funded by \$500 million spread over ten years. This institute would bring BP researchers together with university researchers and would emphasize innovative means of creating and producing fuels from biological sources. In early 2007, the competition was won by a team headed by the University of California Berkeley (UCB) that included the Lawrence Berkeley National Laboratory (LBNL) and the University of Illinois at Urbana-Champaign (UIUC). BP spokespersons indicated that important factors in the selection of the Berkeley-led team were the large and diverse array of distinguished researchers, the tradition of technological innovation and entrepreneurship in the San Francisco Bay Area, and the history of successful, large, interdisciplinary science at LBNL. The recent attention given to the Artemisinin Project and Amyris Biotechnologies, for which the CEO was formerly President of U.S. Fuels Operations for BP, may have been helpful as well.

It is worth noting that LBNL is a laboratory of the U. S. Department of Energy, managed under contract by the University of California system. The inclusion of LBNL thereby brings the federal government into the arrangement. LBNL and the Department of Energy had earlier made major commitments to LBNL's new Helios project, which deals with renewable and solar energy.

The full proposal from the UCB-LBNL-UIUC team and other information on the Energy Biosciences Institute are available³¹. The details of the agreement itself are still being worked out as of this writing. Elements of the arrangement and governance described in the proposal and mentioned elsewhere³² include:

- Construction of a 50,000-square-foot, \$120 million building on University of California land adjoining LBNL to house both the Energy Biosciences Institute and LBNL's Helios project, funded largely by state funds along with some private gifts.
- Use of 35,000 square feet of space in existing buildings on the Berkeley campus for three years before completion and occupancy of the new building.
- Division of the institute into open and proprietary research portions, with fifty BP researchers who will do BP proprietary research accommodated in the building along with UC and LBNL scientists.
- Up to 30% of the total funding being spent on the BP scientists.
- Use of \$100 million of the total funding at UIUC to fund research on crops for ethanol and other biofuels.
- A Director who is both a UCB faculty member and a Faculty Senior Scientist at LBNL, an Associate Director who is a BP employee, and a Deputy Director who is a UIUC faculty member.
- A Governing Board composed of eight senior persons from the various participating organizations (two from BP, one each from UCB, LBNL and UIUC, and the Director, Associate Director and Deputy Director of the Institute).

- Twenty-five themed research teams, seven of which will be located at UIUC.
- Payment of full institutional overhead to UCB and UIUC on all open research funded by BP, with 75% of these indirect costs returned by those institutions to the Energy Biosciences Institute for administrative purposes.
- Intellectual property to be owned by the participating institution that generates it, with BP having the right to license, royalty-free and non-exclusively, inventions made by researchers supported with BP money. Joint inventions will have joint ownership. BP as well has the right to take royalty-bearing exclusive licenses in a time-limited fashion.

An apparent motive for BP in setting up such an institute is close access to leading-edge research in an area that is seen as vital to the future of the corporation. In contrast to the Stanford G-CEP project, the company has placed a high premium on intimate day-to-day interactions of BP researchers with those from the other institutions.

There are a number of potential concerns to be dealt with in the relationship. One is how to handle proprietary research that is being carried out in close proximity with academic and national-laboratory researchers. The presence of proprietary corporate research on a university campus is not unprecedented, however. A second concern, familiar from the Novartis agreement described above, is the preferential position being given by a public university to a single private corporation with regard to the research of a large number of distinguished faculty members. A third concern is the need to ensure academic freedom in the choice and conduct of research. Recognizing such concerns, the Berkeley campus developed the proposal in close consultation with the leadership of the faculty Academic Senate.

Concerns about Industry-University Partnerships and How to Address Them

Several common concerns about industry-university partnerships have been mentioned already in connection with the preceding example. Concerns of this sort have been tallied, explored in a contemplative fashion and balanced against advantages by Bok³³, Calhoun³⁴, and Kirp³⁵, among others. They have also been elaborated from a more uniformly negative point of view by Washburn³⁶.

For the most part, the concerns can be grouped into several categories:

- Companies may unduly influence the research agenda; there will not be free inquiry.
- A conflict of interest occurs when a faculty member has industrial ties and related university research.
- Companies or faculty with ulterior motives may hold back damaging research results. This concern often occurs in connection with clinical trials.
- Public access to knowledge may be restricted. Knowledge that is inherently a public good may go into private hands because of exclusive licensing, publication delay, or not being published at all.
- Cross-fertilization of research may be impeded if universities accept confidentiality arrangements with corporations.
- A conflict of interest may arise if a faculty member determines whether an invention in which s/he has participated belongs to the university, a private entity, or both.

- Reliance upon private funding, such as licensing revenue or corporate research support, or even upon government agency funding, may distort academic purposes and the academic agenda.
- Entrepreneurial faculty may be less engaged in classroom education.
- The humanities and social sciences will decline in attention and importance, because government and industrial funding is primarily directed towards the sciences and engineering. Put another way, the emphasis of the university will go to where the money is.

In the other direction, it must be recognized that academic research would become sterile if not cross-fertilized with industry. As well, the synergy gained by close linkages between universities and industry moves society and the economy forward much more efficaciously than would be the case if interactions did not occur frequently. Also, the nature of financing of public universities by state governments in the United States has changed because of budgetary stringencies and other commitments. Interactions between universities, industry and the government should and must occur. The need is to manage them effectively so as to reap as many of the gains as is consistent with minimizing the concerns.

Universities have instituted, and continue to institute, numerous policies to deal with these concerns, in some cases working within federal or state guidelines. In addition to having policies, universities must have means of monitoring and enforcing them as well. The array of such policies and mechanisms for the University of California can be found at two web sites³⁷, and a more general review has been given by Sugarman³⁸. *Inter alia*, they cover such subjects as conflict of commitment, conflict of interest and disclosure of financial interests, consulting and other activities outside the university, disclosure of inventions, research misconduct, technology licensing, university-industry relations, use of university research facilities, publication policy, patent and copyright policies, research integrity, and reporting of improper activities.

Assessment of What Works Well

As is shown by the measures of success described earlier, the most universal contributions of universities to innovation are the flow of university graduates to both new and established technological companies, along with the flow of research-engaged faculty members themselves to these companies as both founders of start-up ventures and ongoing consultants.

Partnership initiatives of the sorts described above are clearly also very important. The partnerships work best when there are clear incentives for each of the parties to participate. Leveraging the resources of all parties can be attractive. Partnerships should be structured so as to minimize concerns regarding conflicts or improper influences and/or benefits. Potential points of concern should be addressed openly with clear, comprehensive ways of meeting them.

Serious competition and selective choice of awardees are effective avenues toward high-quality projects and partnerships. Examples already cited where competition has clearly been a benefit are the California Institutes for Science and Innovation, the Industry/University Cooperative Research Program, G-CEP and the BP Energy Biosciences Institute. Success breeds success, in the sense that a record of positive accomplishment is reassuring to investors.

Project design and/or active participation by government generally does not work well, because of political influences and contention. Government is best as a silent and enabling partner. This is a reason for the successes of UC CONNECT and the California Council for Science and Technology, as opposed to the short-lived California Technology, Trade and Commerce Agency.

From the viewpoint of industry, the Industry-University Cooperative research and MICRO programs afford ways to select and invest in research where industrial expenses are substantially leveraged with public funds. This is advantageous to both established and start-up companies. The California Institutes for Science and Innovation afforded another way to leverage funds, by assuring that an institute in an area of corporate interest would come into existence, and by establishing liaisons with the institute. Neither of these structures advantaged single or few companies more than others.

In the case of the Artemisinin Project, the Gates Foundation has a different motive – to make a potent anti-malarial drug available at very low cost world-wide. Profit or even recovery of investment are not issues, and that partnership has been constructed in ways and with licensing policies that will lead to the desired very-low-cost product.

University motives include (1) getting research results used in the marketplace and/or for public benefit (a mission of a public university), (2) enabling the conduct of well chosen research, and (3) gaining revenue from licensing, in what should be that order. The Artemisinin Partnership and UC CONNECT address the first goal. The Industry-University Cooperative Research Program, The California Institutes for Science and Innovation, and the Berkeley agreements with BP and Novartis addressed all three goals

For the State of California, the rationale is to foster the establishment of new industries and retention of existing industries, and thereby to build the economy and employment, as well as the standard of living of the state. Second, the state is interested in the overall health of its university system. The Industry-University Cooperative Research Program, the California Institutes for Science and Innovation, the California Council on Science and Technology, the California Institute for Regenerative Medicine, and the state investment in facilities for the BP Energy Biosciences Institute all address that goal, as did the California Technology, Trade and Commerce Agency. The California Institute for Regenerative Medicine has the feature of positioning the state to carry out research and attract scientists in an area currently discouraged by federal government policy. However, it has the drawbacks of lack of flexibility for the State in investing its resources (because of it being locked into the constitution) and attractiveness for political challenge because of both the way it came about and the nature of the research.

Through a variety of different structures and with a number of different motivations, the university has proven to be a powerful driver of technological innovation, creating a fertile environment for California's economy-enhancing industries.

NOTES

¹ Cherisa Yarkin & Andrew Murray, "Assessing the Role of the University of California in the State's Biotechnology Economy: Heightened Impact Over Time", Working Paper No.

02-5, Industry-University Cooperative Research Program, University of California, March 2003.

http://ucdiscoverygrant.org/pdf/UC_Role_in_CA_Biotech_Economy_March2003.pdf.

² Maryann Feldman, “Commercializing Cohen-Boyer”,
http://www.kauffman.org/pdf/tt/Feldman_Maryann.pdf. See also
<http://bancroft.berkeley.edu/Exhibits/Biotech/25.html>

³ Cherisa Yarkin, Andrew Murray & Sam Chou, “The Role of University of California Scientists and Engineers in the State’s R&D-Intensive Communications Industry”, Working Paper No. 03-1, University-Industry Cooperative Research Program, University of California, April 2003.

http://ucdiscoverygrant.org/pdf/UC_Role_in_CA_Communications_Economy_April2003.pdf.

⁴ Lisa Lapin, “A Fine Blend”, UC Davis Magazine, 19, No. 2, 2002.

http://ucdavismagazine.ucdavis.edu/issues/win02/feature_1.html.

⁵ MKF Research LLC, “Economic Impact of California Wine 2006”, MKF Research LLC, 2006. See also

http://www.wineinstitute.org/industry/statistics/2006/ca_wine_economic_impact.php.

⁶ The Wine Institute, “California Wine Statistical Highlights”, September 2006.

http://www.wineinstitute.org/industry/statistics/2004/ca_industry_highlights.php.

⁷ ICF Consulting, “California’s Future: It Starts Here”, report prepared for University of California, March 2003.

<http://www.universityofcalifornia.edu/itstartshere/report/fullreport.pdf>.

⁸ AnnaLee Saxenian, *Regional Advantage: Culture and Competition in Silicon Valley and Route 128*, Harvard University Press, Cambridge MA, New Ed., 1996.

⁹ C. S. Gillmor, *Fred Terman at Stanford: Building a Discipline, a University, and Silicon Valley*, Stanford University Press, Stanford CA, 2004.

¹⁰ <http://www.ucop.edu/research/micro/>

¹¹ <http://www.ucdiscoverygrant.org/AnnualReport.pdf>; <http://www.ucdiscoverygrant.org/>.

¹² <http://www.connect.org/>

¹³ <http://www.connect.ucdavis.edu/home.cfm?id=OVC,6>

¹⁴ <http://www.connect.org/programs/index.htm>

¹⁵ <http://www.ccst.us/>

¹⁶ Brenda Foust, “The California Institutes for Science and Innovation (Cal ISIs)”, The Senate Source, University of California, January 2005.

<http://www.universityofcalifornia.edu/senate/news/source/Calisi.pdf> See also

<http://www.ucop.edu/california-institutes/>.

¹⁷ http://www.yubanet.com/artman/publish/printer_48308.shtml

¹⁸ <http://www.cirm.ca.gov/>

¹⁹ <http://www.cirm.ca.gov/prop71/pdf/prop71.pdf>

²⁰ http://www.signonsandiego.com/uniontrib/20041219/news_1n19stemcell.html

²¹ <http://www.voterguide.ss.ca.gov/props/prop87/prop87.html>

²² Todd LaPorte, “Diluting Public Patrimony or Inventive Response to Increasing Knowledge Asymmetries: Watershed for Land Grant Universities? Reflections on the University of California, Berkeley – Novartis Agreement”, in Commission on Physical Sciences, Mathematics and Applications, *Research Teams and Partnerships: Trends in Chemical Sciences, Report of a Workshop*, pp. 66-84, National Research Council, National Academy Press, Washington DC, 2000.

<http://www.nap.edu/openbook/0309068274/html/66.html>

²³ <http://www.berkeley.edu/news/media/releases/98legacy/11-23-98.html>

- ²⁴ Eyal Press and Jennifer Washburn, "The Kept University: U. C. Berkeley's Recent Agreement with a Swiss Pharmaceutical Company Has Raised Concerns Over Who Ultimately Directs Research", *Atlantic Monthly*, 285, No. 3, 39-54 (2000). See also <http://www.aaas.org/spp/rd/ch26.pdf>
- ²⁵ Lawrence Busch, R. Allison, C. Harris, A. Rudy, B. T. Shaw, T. Ten Eyck, D. Coppin, J. Konefal, and C. Oliver, "External Review of the Collaborative Research Agreement between Novartis Agricultural Discovery Institute, Inc and The Regents of the University of California", Inst. For Food and Agricultural Standards, Michigan State University, July 13, 2004.
<http://evcp.chance.berkeley.edu/documents/Reports/documents/NovartisBerkeleyFinalReport071204.pdf>
- ²⁶ A. P. Rudy, D. Coppin, J. Konefal, B. T. Shaw, T. A. Ten Eyck, C. Harris and L. Busch, *Universities in the Age of Corporate Science: The UC-Novartis Controversy*, Temple University Press, Philadelphia PA, 2007.
- ²⁷ <http://www.artemisininproject.org/>
- ²⁸ <http://www.tmgh.org/case-studies-treatment-for-malaria.php>
- ²⁹ <http://gcep.stanford.edu/>
- ³⁰ http://gcep.stanford.edu/pdfs/gcep_agreement.pdf
- ³¹ "Energy Biosciences Institute", <http://www.ebiweb.org>.
- ³² Eli Kintisch, "BP Bets Big on UC Berkeley for Novel Biofuels Center", *Science*, 315, pp. 746, 790, February 9, 2007.
- ³³ Derek Bok, "Universities in the Marketplace", Princeton University Press, Princeton NJ, 2003.
- ³⁴ Craig Calhoun, "Is the University in Crisis?", *Society*, 43, No. 4, 8-18, 2006.
- ³⁵ D. L. Kirp, "Shakespeare, Einstein, and the Bottom Line", Harvard University Press, Cambridge MA, 2003.
- ³⁶ Jennifer Washburn, "University Inc.: The Corporate Corruption of Higher Education", Basic Books, New York NY, 2005.
- ³⁷ <http://www.research.chance.berkeley.edu/main.cfm?id=9>;
<http://www.ucop.edu/research/policies/welcome>.
- ³⁸ S. D. Sugarman, "Conflicts of Interest in the Roles of the University Professor", *Theoretical Inquiries in Law*, 6, No. 1, 255-275, 2005.